Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Dragana Milojkovic, Jane F. Apperley, Gareth Gerrard, Amr R. Ibrahim, Richard Szydlo, Marco Bua, Alistair Reid, Katayoun Rezvani, Letizia Foroni, John Goldman, David Marin

Blood (2012) 119 (8): 1838–1843.

https://doi.org/10.1182/blood-2011-10-383000

Published: 2012

Journal Articles

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Blood (2011) 118 (21): 3753.

https://doi.org/10.1182/blood.V118.21.3753.3753

Published: 2011

Journal Articles

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Dragana Milojkovic, MD, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Amr R Ibrahim, Marco Bua, MD, Alistair Reid, PhD, Gareth Gerrard, PhD, Letizia Foroni, MD PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 3777.

https://doi.org/10.1182/blood.V118.21.3777.3777

Published: 2011

Journal Articles

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Dragana Milojkovic, MD, Amr R Ibrahim, Letizia Foroni, MD PhD, Claire Lucas, Gareth Gerrard, PhD, Lihui Wang, Richard M Szydlo, Richard E Clark, Jane F Apperley, MBChB, MD, FRCP, FRCPath, Marco Bua, MD, Jiri Pavlu, Christos Paliompeis, Alistair Reid, PhD, Katy Rezvani, MBBS, PhD, MRCP, FRCPath, John M Goldman, David Marin

Blood (2011) 118 (21): 1680.

https://doi.org/10.1182/blood.V118.21.1680.1680

Published: 2011

Journal Articles

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Amr R. Ibrahim, Lina Eliasson, Jane F. Apperley, Dragana Milojkovic, Marco Bua, Richard Szydlo, Francois-Xavier Mahon, Kasia Kozlowski, Christos Paliompeis, Letizia Foroni, Jamshid S. Khorashad, Alex Bazeos, Mathieu Molimard, Alistair Reid, Katayoun Rezvani, Gareth Gerrard, John Goldman, David Marin

Blood (2011) 117 (14): 3733–3736.

https://doi.org/10.1182/blood-2010-10-309807

Published: 2011

Journal Articles

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Amr R. Ibrahim, Christos Paliompeis, Marco Bua, Dragana Milojkovic, Richard Szydlo, Jamshid S. Khorashad, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, Francesco Dazzi, Jane F. Apperley, John M. Goldman, David Marin

Blood (2010) 116 (25): 5497–5500.

https://doi.org/10.1182/blood-2010-06-291922

Published: 2010

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Amr R Ibrahim, Marco Bua, Jamshid S Khorshad, Dragana Milojkovic, Lina Eliasson, Richard Szydlo, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 2274.

https://doi.org/10.1182/blood.V116.21.2274.2274

Published: 2010

Journal Articles

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R Ibrahim, Dragana Milojkovic, Marco Bua, Jamshid S Khorshad, Richard Szydlo, Lina Eliasson, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 3414.

https://doi.org/10.1182/blood.V116.21.3414.3414

Published: 2010

NARROW

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients

Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,

Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients,

Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only